Dopaminergic Mechanisms in Neurodegenerative Disorders

Maintaining dopaminergic function is central to motor control, reward processing and cognitive health. In Parkinson’s disease and related neurodegenerative disorders, the progressive death of dopaminergic neurones in the substantia nigra pars compacta underlies hallmark motor impairments. Physiologically, dopamine is synthesised from tyrosine, sequestered in synaptic vesicles and released into the synaptic cleft before reuptake or enzymic degradation by monoamine oxidase and aldehyde dehydrogenase. Perturbations at any stage generate cytotoxic intermediates, notably 3,4-dihydroxyphenylacetaldehyde (DOPAL), which can form reactive quinones, induce oxidative stress and promote α-synuclein misfolding. Accumulation of misfolded α-synuclein and impaired autophagy-lysosomal function further exacerbate neuronal vulnerability. Interconnections between dysfunctional dopamine metabolism, protein aggregation and energy failure have emerged as key drivers of pathogenesis. A detailed understanding of these mechanisms is crucial for the development of targeted neuroprotective strategies, which hold global relevance given the rising prevalence of ageing populations.

Research from Nature Portfolio

Recent investigations have elucidated how DOPAL modification of α-synuclein drives dopaminergic degeneration. Foundational work demonstrated that DOPAL-induced oligomers permeabilise synaptic vesicle membranes, causing dopamine leakage that perpetuates a toxic feedback loop. This cycle compromises vesicle dynamics and synaptic transmission, overwhelming cellular proteostasis mechanisms. These insights establish a direct link between dopamine catabolite chemistry and synucleinopathy, offering novel molecular targets to interrupt the DOPAL–α-synuclein interaction and preserve synaptic integrity.

Dopaminergic Mechanisms in Neurodegenerative Disorders publication trend

The graph below shows the total number of articles in dopaminergic mechanisms in neurodegenerative disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Dopaminergic neurones: Neurones that synthesise and release dopamine to mediate motor and cognitive functions.

Substantia nigra pars compacta: A midbrain region rich in dopaminergic neurones, critically affected in Parkinson’s disease.

α-Synuclein: A presynaptic protein prone to misfolding and aggregation in neurodegenerative disorders.

3,4-Dihydroxyphenylacetaldehyde (DOPAL): A toxic intermediary metabolite of dopamine implicated in protein modification and neuronal death.

Proteostasis: The maintenance of cellular protein homeostasis through synthesis, folding and degradation pathways.

Autophagy-lysosomal pathway: Cellular mechanism for degrading and recycling damaged organelles and protein aggregates.

Glycolysis: Metabolic pathway converting glucose to pyruvate, generating ATP to support neuronal energy demands.

References

1. Role of dopamine in the pathophysiology of Parkinson’s disease. Translational Neurodegeneration (2023).
2. DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Scientific Reports (2017).
3. Impaired dopamine metabolism in Parkinson’s disease pathogenesis. Molecular Neurodegeneration (2019).
4. DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease. npj Parkinson's Disease (2023).
5. Dopamine modification of glycolytic enzymes impairs glycolysis: possible implications for Parkinson’s disease. Cell Communication and Signaling (2024).